Related Experiment Videos
Stinging insect allergy
1Department of Medicine, State University of New York, Buffalo School of Medicine.
The Medical Clinics of North America
|July 1, 1992
Summary
Insect sting anaphylaxis affects many, causing severe reactions in about half of patients. Venom immunotherapy offers nearly 100% protection against future stings.
Area of Science:
- Allergy and Immunology
- Toxicology
- Public Health
Background:
- Insect sting anaphylaxis is a significant health concern, affecting 0.4% of the population and causing 40 US deaths annually.
- Reactions are IgE-mediated, targeting venoms from Hymenoptera insects like bees, wasps, hornets, and fire ants.
- Anaphylactic symptoms vary, with children often experiencing mild dermal reactions, while adults are more prone to severe systemic responses.
Purpose of the Study:
- To review the epidemiology, clinical presentation, natural history, and management of insect sting anaphylaxis.
- To highlight the efficacy of venom immunotherapy in preventing recurrent anaphylactic reactions.
- To discuss evolving recommendations for immunotherapy duration.
Main Methods:
- Review of existing literature on insect sting anaphylaxis.
- Analysis of epidemiological data and clinical outcomes.
- Evaluation of the effectiveness of venom immunotherapy and skin testing.
Main Results:
- Approximately 50% of patients experience recurrent allergic reactions to subsequent stings.
- Children with only dermal reactions have a benign prognosis; severe reactions risk recurrence.
- Venom immunotherapy provides near 100% protection, with 3 years often sufficient.
Conclusions:
- Insect sting anaphylaxis requires prompt management, including epinephrine availability for at-risk individuals.
- Venom immunotherapy is highly effective in preventing anaphylaxis from insect stings.
- Immunotherapy duration is adaptable, potentially shortened if skin tests normalize or after 3 years.